Pediatrics | Eklavya Medical

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 191 person Asked by .

bookmark_add

Pediatric Cardiomyopathies (DCM, HCM, RCM)

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q148 · DNB/MD 2021/2

Pediatric Cardiomyopathies (DCM, HCM, RCM)

Examiner's Intent: Expects clear pathophysiological/functional distinction between the three major cardiomyopathy categories, awareness of the diverse genetic/etiological landscape, and general heart failure management principles adapted to each specific pattern.

Feature	Dilated (DCM)	Hypertrophic (HCM)	Restrictive (RCM)
Core defect	Ventricular dilation, impaired systolic function	Inappropriate LV hypertrophy (no HTN/AS to explain it)	Impaired diastolic filling/relaxation; stiff, non-compliant walls; systolic function preserved
Frequency	Most common pediatric cardiomyopathy overall	Common; sarcomeric gene mutations (autosomal dominant, e.g. beta-myosin heavy chain, MYBPC3)	Least common of the three
Etiology	Idiopathic, genetic, post-viral/post-myocarditis, metabolic/mitochondrial	Sarcomeric protein gene mutations	Idiopathic; infiltrative causes rarer in children than adults (e.g., amyloidosis uncommon)
Key risk/complication	Progressive heart failure	Dynamic LVOT obstruction; sudden cardiac death in young athletes (obstruction + ischemia + malignant arrhythmia)	Poor prognosis; limited effectiveness of standard HF pharmacotherapy; earlier need for transplant
Management	ACEi/ARB, beta-blockers, diuretics; mechanical support/transplant for refractory disease	Beta-blockers or CCBs first-line; ICD for high-risk sudden death criteria; activity restriction individualized	Predominantly supportive (diuretics, avoid excessive preload reduction); earlier transplant consideration

Clinical Evaluation (All Categories)

Echocardiography — defines structural/functional pattern
ECG — arrhythmia risk assessment (particularly important in HCM)
Genetic testing and family screening — where a genetic cause is suspected (especially HCM and increasingly DCM)

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 192 person Asked by .

bookmark_add

Patent Ductus Arteriosus (PDA) & Atrial Septal Defect (ASD)

description Clinical Response

Q149 · DNB/MD 2020/2

Patent Ductus Arteriosus (PDA) & ASD

Examiner's Intent: Expects the classic hemodynamic/auscultatory findings for term-infant/older-child PDA (distinct from the preterm-specific hsPDA in Section 1, Q16), and the general indications for transcatheter closure of both PDA and ASD.

Hemodynamics and Clinical Features of PDA (Term Infant/Older Child)

Persistent left-to-right shunt (aorta → pulmonary artery) causes chronic pulmonary overcirculation and left heart volume overload; long-term risks include infective endarteritis and, if uncorrected, progression to Eisenmenger physiology (analogous to VSD, Q143). Closure is warranted essentially regardless of size.

Finding	Description
Murmur	Classic continuous “machinery” murmur (throughout systole and diastole), best heard at left infraclavicular/upper left sternal border
Pulse pressure	Wide (diastolic “runoff” from aorta into pulmonary circulation)
Pulses	Bounding peripheral pulses

Atrial Septal Defect (ASD)

Typically subtler findings than PDA/VSD — often incidental. Systolic ejection murmur at upper left sternal border (increased flow across normal pulmonary valve) + characteristic fixed, widely split S2 (delayed pulmonary valve closure from chronic right-sided volume load; fixed = does not vary with respiration).

Transcatheter Device Closure Indications

Defect	Closure Indication
PDA	Essentially any persistent PDA in a term infant/older child beyond early infancy
Secundum ASD	Hemodynamically significant defects with right heart volume overload (RV/RA enlargement on echo); small, insignificant defects (e.g., small PFO-type) may be observed

Transcatheter closure avoids thoracotomy/cardiopulmonary bypass, offers shorter recovery, and excellent long-term outcomes in appropriately selected patients with favorable anatomy.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 193 person Asked by .

bookmark_add

Pulmonary Arterial Hypertension (PAH) in Children

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q150 · DNB/MD 2019/2

Pulmonary Arterial Hypertension (PAH) in Children

Examiner's Intent: Expects awareness of the classification framework for pediatric PAH and the major targeted pharmacological therapy classes now available, reflecting the field's substantial therapeutic evolution beyond purely supportive management.

Definition and Classification

Hemodynamically defined by elevated mean pulmonary artery pressure exceeding a defined threshold on cardiac catheterization. In children, most commonly associated with congenital heart disease (large, uncorrected left-to-right shunts progressing toward Eisenmenger physiology — Q143), though also occurs as idiopathic/heritable PAH and with chronic lung disease, connective tissue disease, and other conditions.

Targeted Medical Therapies

Drug Class	Example Agents	Mechanism	Key Consideration
Endothelin Receptor Antagonists	Bosentan	Block endothelin-1 (vasoconstrictor/mitogen)	Monitor for hepatotoxicity
PDE-5 Inhibitors	Sildenafil	Prevent cGMP breakdown (NO pathway) — sustained vasodilation	Analogous mechanism to sildenafil use in neonatal PPHN (Section 1, Q7)
Prostacyclin analogs	Inhaled/oral/IV/SC formulations	Prostacyclin receptor activation — vasodilation + anti-proliferative	Reserved for severe/advanced disease; continuous infusion risks severe rebound PH if abruptly stopped

Treatment Approach

Contemporary management increasingly uses combination therapy across multiple classes for severe disease, guided by functional class, hemodynamics on catheterization, and treatment response over time.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 194 person Asked by .

bookmark_add

Total Anomalous Pulmonary Venous Connection (TAPVC)

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q151 · DNB/MD 2018/1

Total Anomalous Pulmonary Venous Connection (TAPVC)

Examiner's Intent: Expects the anatomical classification by drainage site, and the critical clinical distinction between obstructed and unobstructed TAPVC given their markedly different presentation urgency and management implications.

Anatomical Types

Type	Drainage Site	Notes
Supracardiac	Anomalous vertical vein → innominate vein/SVC	Most common type
Cardiac	Directly into coronary sinus or right atrium	—
Infracardiac	Vessel traverses diaphragm → portal venous system/IVC	Particularly high obstruction risk (long, narrow pathway)
Mixed	Combination of the above patterns	—

[Diagram: TAPVC anatomical types diagram: supracardiac, cardiac, infracardiac, mixed drainage pathways to systemic venous system]

Note: Since pulmonary venous return does not reach the LA directly, survival requires an obligatory right-to-left shunt (PFO/ASD) — analogous in criticality to intercirculatory mixing in TGA (Q145).

Clinical Features — Obstructed vs Unobstructed

	Unobstructed TAPVC	Obstructed TAPVC
Presentation	Mild-moderate cyanosis, pulmonary overcirculation/heart failure signs (tachypnea, poor feeding, FTT) over weeks	Severe, rapidly progressive respiratory distress and profound cyanosis, essentially from birth
Mechanism	Mixing of systemic/pulmonary venous blood at atrial level	Mechanical obstruction → severe pulmonary venous hypertension and pulmonary edema
Urgency	Allows elective diagnostic evaluation/surgical planning	Genuine neonatal emergency — same-day/emergency surgery (cannot be medically palliated)
Typical type	Any type	Particularly characteristic of infracardiac type

Surgical Repair

Anastomosis of the common pulmonary venous confluence directly to the left atrium, with ligation of the anomalous connection and closure of the atrial-level communication. Timing: emergency, same-admission for obstructed TAPVC vs. elective but prompt for unobstructed TAPVC.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 195 person Asked by .

bookmark_add

Myocarditis in Children

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q152 · DNB/MD 2017/1

Myocarditis in Children

Examiner's Intent: Expects awareness of the common viral etiologies, recognition that myocarditis can closely mimic sepsis (paralleling the HLH-sepsis mimicry in Q130), appropriate biomarker use, and predominantly supportive management principles.

Etiology

Most commonly viral: Coxsackievirus (classically Coxsackie B), Adenovirus, Parvovirus B19. Mechanism: direct viral cytopathic myocardial injury plus subsequent immune-mediated inflammatory injury — the latter can persist and evolve into chronic dilated cardiomyopathy (Q148).

Clinical Presentation — A Diagnostic Mimicker of Sepsis

Diagnostic Pitfall: Myocarditis can closely mimic septic shock (fever, tachycardia, poor perfusion, cardiogenic shock) — the two require fundamentally different initial management, particularly regarding fluid resuscitation: aggressive boluses appropriate for typical septic shock can precipitate decompensation/pulmonary edema in myocarditis-associated myocardial dysfunction.

Suspect myocarditis with disproportionately poor cardiac-specific findings (gallop rhythm, hepatomegaly, echocardiographic ventricular dysfunction) relative to apparent infectious severity.

Biomarker Evaluation

Test	Finding/Role
Troponin I	Elevated — reflects direct myocardial injury; relatively specific
NT-proBNP (or BNP)	Elevated — reflects ventricular wall stress/dysfunction; useful for monitoring trajectory
Echocardiography	Assesses degree of ventricular systolic dysfunction; excludes other structural abnormalities
Endomyocardial biopsy	Historical gold standard; used selectively (invasive, imperfect sensitivity due to patchy myocardial inflammation)
Cardiac MRI	Increasingly used non-invasive adjunct — tissue characterization suggestive of inflammation/edema

Supportive Management

Careful, judicious fluid management — avoid precipitating pulmonary edema
Inotropic support for significant cardiogenic shock
ECMO as a bridge to recovery for severe, refractory cases — favorable myocardial recovery potential if adequately supported
IVIG — used adjunctively in some centers; evidence base remains an area of ongoing study

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 196 person Asked by .

bookmark_add

Congenital Heart Defects Presenting in First Week of Life

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q153 · DNB/MD 2015/2

Congenital Heart Defects Presenting in First Week of Life

Examiner's Intent: Expects the fundamental conceptual distinction between ductal-dependent systemic and ductal-dependent pulmonary circulation lesions — a unifying framework connecting numerous individual lesions discussed elsewhere in this section — and clear PGE1-centered emergency stabilization principles.

Category	Mechanism	Example Lesions
Ductal-Dependent Systemic Circulation	Severe left-sided obstruction — systemic perfusion depends on right-to-left flow through the ductus	Severe coarctation of the aorta (Q144), critical aortic stenosis, interrupted aortic arch, Hypoplastic Left Heart Syndrome (most severe end of spectrum)
Ductal-Dependent Pulmonary Circulation	Severe right-sided obstruction — pulmonary blood flow depends on left-to-right flow through the ductus	Severe/critical pulmonary stenosis, pulmonary atresia (± VSD), Tricuspid Atresia with pulmonary stenosis/atresia

The Unifying Clinical Principle

Key Pattern: Infants with either category typically appear entirely well immediately after birth (ductal patency compensates), then develop progressive, dramatic deterioration over days 2–4 of life as the ductus undergoes normal postnatal closure — a seemingly healthy newborn who suddenly deteriorates should immediately prompt consideration of ductal-dependent CHD.

[Diagram: Timeline diagram: birth (well) → day 1-2 (ductus patent, stable) → day 2-4 (ductal closure, deterioration) → PGE1 initiation]

Prostaglandin E1 Therapy and Emergency Stabilization

Immediate PGE1 infusion to re-open or maintain ductal patency is the essential, life-saving intervention for either category — providing physiological stabilization pending echocardiography and surgical/interventional planning.

Exam Pearl: Clinical pattern-recognition principle: “well newborn, sudden deterioration around day 2–4, consider ductal-dependent CHD, start PGE1 immediately.”

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 197 person Asked by .

bookmark_add

Infective Endocarditis Prophylaxis

description Clinical Response

Q154 · DNB/MD 2010/1

Infective Endocarditis Prophylaxis

Examiner's Intent: Expects awareness of the significant contraction in prophylaxis recommendations reflected in current AHA guidance, and precise knowledge of which specific cardiac conditions remain in the highest-risk category still warranting prophylaxis.

Practice Evolution: Current AHA guidelines represent a substantial contraction from older, more expansive prophylaxis recommendations — reflecting evidence questioning prophylaxis effectiveness for lower-risk conditions (routine activities like toothbrushing likely pose greater cumulative bacteremia risk than brief procedure-associated bacteremia) and concern regarding unnecessary antibiotic exposure/resistance.

High-Risk Cardiac Conditions Requiring Prophylaxis

Prosthetic cardiac valves (or prosthetic material used for valve repair)
Previous history of infective endocarditis
Unrepaired cyanotic congenital heart disease, including palliative shunts/conduits
Completely repaired CHD with prosthetic material/device — first 6 months following repair only
Repaired CHD with residual defects at or adjacent to a prosthetic patch/device site
Cardiac transplant recipients who develop valvulopathy

Important Exclusions: No longer considered to warrant prophylaxis: isolated secundum ASD, surgically repaired ASD/VSD/PDA without residual defect (beyond the 6-month window), mitral valve prolapse without significant regurgitation.

Procedures Requiring Prophylaxis

Recommended specifically for dental procedures involving manipulation of gingival tissue or the periapical region of teeth, or perforation of the oral mucosa (transient bacteremia, predominantly viridans group streptococci). Generally not recommended for most GI or GU procedures.

Standard Prophylactic Regimen

Scenario	Regimen
Standard	Amoxicillin 50 mg/kg (up to adult dose), single oral dose, 30–60 minutes before the procedure
Penicillin allergy	Alternative regimens including clindamycin, following the same pre-procedure timing principle

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 198 person Asked by .

bookmark_add

Cystic Fibrosis (CF) & CFTR Modulators

description Clinical Response

Q155 ★ · DNB/MD 2025/1

Cystic Fibrosis (CF) & CFTR Modulators

Examiner's Intent: CF represents the paradigm example of “genotype-driven precision medicine” in pediatrics; examiners expect articulation of why CFTR mutation class matters for treatment selection — a transformative area given the recent modulator therapy revolution — alongside the classic multisystem phenotype and diagnostic criteria.

Pathophysiology

CF results from mutations in the CFTR gene, encoding a chloride channel on the apical membrane of epithelial cells (airway, pancreas, intestine, sweat glands, vas deferens). Dysfunction impairs chloride/water transport → thick, viscous secretions.

Organ	Effect
Airway	Impaired mucociliary clearance → chronic infection, progressive bronchiectasis
Pancreas	Duct obstruction → exocrine (later endocrine) pancreatic insufficiency
Sweat glands	Paradoxical excessive chloride/sodium loss into sweat (CFTR normally reabsorbs Cl⁻ from sweat duct) — basis of sweat chloride test

Clinical Spectrum

Respiratory: chronic productive cough, recurrent infections (early S. aureus/H. influenzae; Pseudomonas aeruginosa colonization, especially mucoid phenotype, → important prognostic milestone), progressive bronchiectasis, eventual respiratory failure
GI: meconium ileus (classic early presentation), distal intestinal obstruction syndrome, rectal prolapse
Pancreatic: exocrine insufficiency → malabsorption, steatorrhea, fat-soluble vitamin (A, D, E, K) deficiency; progressive endocrine involvement → CF-related diabetes

Sweat Chloride Test

Sweat Chloride	Interpretation
≥ 60 mmol/L	Diagnostic of CF
30–59 mmol/L	Intermediate/equivocal — further evaluation needed
< 30 mmol/L	Normal/CF unlikely

Uses pilocarpine iontophoresis; technically more challenging in very young infants (relevant for newborn-screen confirmatory testing).

Genetic Testing and CFTR Mutation Classes

Class	Molecular Defect
I	Defective protein synthesis (nonsense/frameshift — no functional protein)
II	Defective processing/trafficking — most common, exemplified by F508del (most prevalent CFTR mutation globally)
III	Defective channel regulation/gating
IV	Defective channel conductance
V	Reduced quantity of otherwise normal CFTR protein
VI	Reduced protein stability at cell membrane

CFTR Modulator Therapy — A Transformative Advance

Modulator Type	Agent(s)	Mechanism	Target
Potentiator	Ivacaftor	↑ open probability/gating of CFTR at the membrane	Class III gating mutations
Correctors	Lumacaftor, Tezacaftor, Elexacaftor	Improve folding/trafficking of mutant protein	Class II (F508del)
Triple combination	Elexacaftor/Tezacaftor/Ivacaftor	2 correctors + 1 potentiator	≥1 F508del allele — dramatic clinical benefit (lung function, exacerbations, weight gain)

Note: The triple combination represents the single most significant recent therapeutic advance in CF — a genuine paradigm shift from symptomatic management to disease-modifying, genotype-targeted precision therapy.

Supportive Management

Airway clearance therapy (chest physiotherapy, mechanical devices)
Mucolytic therapy (dornase alfa, hypertonic saline)
Pancreatic enzyme replacement therapy
Fat-soluble vitamin supplementation
High-calorie nutritional support
Prompt antibiotic therapy for exacerbations, guided by respiratory culture surveillance

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 199 person Asked by .

bookmark_add

Community-Acquired Pneumonia (CAP) & Empyema

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q156 ★ · DNB/MD 2024/2

Community-Acquired Pneumonia (CAP) & Empyema

Examiner's Intent: Expects age-stratified etiological knowledge directly informing empiric antibiotic choice, clear hospitalization criteria, and the specific stepwise management algorithm for parapneumonic effusion/empyema.

Etiology by Age

Age Group	Predominant Organisms
Neonates	Group B Streptococcus, Gram-negative enterics (shared vertical transmission routes with early-onset sepsis)
Infants/young children (<5 years)	Predominantly viral (RSV, parainfluenza, influenza); Streptococcus pneumoniae most important bacterial cause; H. influenzae type b now uncommon post-Hib vaccination
Older children/adolescents	S. pneumoniae remains important; atypical organisms (Mycoplasma pneumoniae, less commonly Chlamydia pneumoniae) increasingly prevalent — “walking pneumonia” pattern with extrapulmonary features

Indications for Hospitalization

Significant hypoxemia (SpO2 <90–92% on room air)
Significant respiratory distress (marked tachypnea, retractions, grunting)
Inability to maintain adequate oral hydration/feeding
Young infant age (particularly <3–6 months)
Significant underlying comorbidity (chronic cardiopulmonary disease, immunocompromise)
Evidence of complicated pneumonia (parapneumonic effusion/empyema)
Failure of outpatient antibiotic therapy

Empiric Antibiotic Selection

Scenario	First-Line Therapy
Uncomplicated, presumed bacterial CAP requiring hospitalization (healthy, fully-immunized)	IV Ampicillin (or Penicillin) — reflects preserved pneumococcal penicillin susceptibility in vaccinated children
More severely ill / incompletely immunized / high pneumococcal resistance setting	Third-generation cephalosporin
Suspected atypical pneumonia (older children, indolent pattern)	Macrolide (azithromycin) added or as primary therapy

Management of Parapneumonic Effusion/Empyema — Stepwise Escalation

Simple, small effusion — continued antibiotics alone, no drainage
Larger/complicated effusion causing respiratory compromise — thoracocentesis (diagnostic + therapeutic); pleural fluid analysis (cell count, Gram stain/culture, pH, glucose, LDH)
Established empyema or rapid reaccumulation — tube thoracostomy + intrapleural fibrinolytic therapy (e.g., alteplase) to break down loculations
Failure of chest tube + fibrinolytics, or extensive multiloculated empyema — VATS (Video-Assisted Thoracoscopic Surgery) for debridement/decortication

[Diagram: Stepwise empyema management flowchart: antibiotics alone → thoracocentesis → chest tube + fibrinolytics → VATS]

Note: Deliberate strategy: use the least invasive effective intervention at each stage, reserving surgery for genuinely refractory cases.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 200 person Asked by .

bookmark_add

Chronic & Recurrent Diarrhea / Celiac Disease

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

Q157 · DNB/MD 2024/1

Chronic & Recurrent Diarrhea / Celiac Disease

Examiner's Intent: Expects the current ESPGHAN non-biopsy diagnostic pathway (a significant, relatively recent evolution from mandatory biopsy-based diagnosis), and a structured differential diagnosis approach to chronic diarrhea more broadly.

ESPGHAN Non-Biopsy Diagnostic Criteria for Celiac Disease

Diagnosis without biopsy is permitted in symptomatic children meeting all of the following:

Anti-tissue transglutaminase (anti-tTG) IgA titer ≥10× the upper limit of normal
Positive anti-endomysial antibody (EMA) on a separate blood sample
Compatible genetic background (HLA-DQ2 and/or HLA-DQ8 positive)

Note: Biopsy remains required for lower-titer antibody elevations, asymptomatic screen-detected children, or any diagnostic uncertainty — the non-biopsy pathway applies only where serological/genetic confidence is sufficiently high.

Broader Workup for Chronic Diarrhea

Cause	Key Features
Inflammatory Bowel Disease	Detailed in Q161
Cow’s Milk Protein Allergy	Especially in infants — diarrhea ± blood/mucus, poor growth, atopic features; resolves with dietary elimination
Autoimmune Enteropathy	Rare; immune-mediated mucosal injury, particularly in infants; sometimes part of broader immunodysregulation syndrome; requires immunosuppressive rather than dietary management

Diagnostic pathway is guided by age, associated features (blood in stool, growth pattern, extraintestinal manifestations), and targeted serological/endoscopic evaluation.

Pediatric Cardiomyopathies (DCM, HCM, RCM)

Clinical Evaluation (All Categories)

Patent Ductus Arteriosus (PDA) & Atrial Septal Defect (ASD)

Hemodynamics and Clinical Features of PDA (Term Infant/Older Child)

Atrial Septal Defect (ASD)

Transcatheter Device Closure Indications

Pulmonary Arterial Hypertension (PAH) in Children

Definition and Classification

Targeted Medical Therapies

Treatment Approach

Total Anomalous Pulmonary Venous Connection (TAPVC)

Anatomical Types

Clinical Features — Obstructed vs Unobstructed

Surgical Repair

Myocarditis in Children

Etiology

Clinical Presentation — A Diagnostic Mimicker of Sepsis

Biomarker Evaluation

Supportive Management

Congenital Heart Defects Presenting in First Week of Life

The Unifying Clinical Principle

Prostaglandin E1 Therapy and Emergency Stabilization

Infective Endocarditis Prophylaxis

High-Risk Cardiac Conditions Requiring Prophylaxis

Procedures Requiring Prophylaxis

Standard Prophylactic Regimen

Cystic Fibrosis (CF) & CFTR Modulators

Pathophysiology

Clinical Spectrum

Sweat Chloride Test

Genetic Testing and CFTR Mutation Classes

CFTR Modulator Therapy — A Transformative Advance

Supportive Management

Community-Acquired Pneumonia (CAP) & Empyema

Etiology by Age

Indications for Hospitalization

Empiric Antibiotic Selection

Management of Parapneumonic Effusion/Empyema — Stepwise Escalation

Chronic & Recurrent Diarrhea / Celiac Disease

ESPGHAN Non-Biopsy Diagnostic Criteria for Celiac Disease

Broader Workup for Chronic Diarrhea

Subcategory Tree

Category Subscription

Anatomical Models

Case Reviews